CMSC INforMS: Multiple sclerosis risk higher in rosacea-affected women: Study
Wednesday, May 18, 2016
Posted by: Elizabeth Porco
Multiple sclerosis risk has been found to be higher in rosacea-affected women. The study was conducted by researchers from the University of Copenhagen who found a higher risk of multiple sclerosis in women with rosacea, compared to women without the skin condition.
The study looked at patients diagnosed with rosacea between January 1997 and December 2011. Each of the subjects was matched with five controls, with 6,759 rosacea patients and 33,795 controls in total.
The researchers then identified patients with multiple sclerosis and found that rosacea patients had a 1.5-fold increased risk of multiple sclerosis, compared to those without rosacea. When the participants were divided by gender, the association was only seen in women.
The study only observed the trend and cannot establish a cause-and-effect relationship. Additional research is required to uncover the underlying mechanisms that could be contributing to the association.
Skin problems caused by a common treatment for multiple sclerosis
An alternative study found that skin problems could be caused by a common treatment method for multiple sclerosis known as interferon-β. Interferon-β is prescribed as a means to suppress the immune system, which wrongfully attacks the myelin and thus promotes the onset of multiple sclerosis.
Like many other medications, interferon-β comes along with some side effects, so weighing out the pros and cons of these side effects could help determine if the medication is worth it or not.
The researchers found that side effects of interferon-β could affect the skin, more specifically, cause new-onset psoriasis.
The researchers suggest that physicians need to take this side effect into account when prescribing interferon-β to their patients. The authors concluded, “We think that neurologists should be aware of systemic cutaneous side effects and have a closer look on interferon-associated skin lesions. Detection of psoriasiform lesions might indicate that interferons are probably not beneficial in the individual situation. We suggest that skin lesions may serve as biomarkers to allocate MS patients to adequate disease-modifying drugs.”
Bel Marra Health
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.